Navigation Links
Progentix Orthobiology and NuVasive Sign Investment Agreement
Date:1/14/2009

BILTHOVEN, The Netherlands, January 14 /PRNewswire/ -- Progentix Orthobiology B.V. announced today that it has closed an investment agreement with NuVasive, a medical device company focused on developing products for minimally disruptive surgical treatments for the spine. Under the terms of the agreement NuVasive will gain access to Progentix' synthetic bone substitutes designed to accelerate bone healing through a novel micro-structure created by a proprietary manufacturing process.

NuVasive's initial commitment will be $15 million in cash, consisting of a $10 million equity purchase from Progentix shareholders and a $5 million loan used to fund ongoing clinical and regulatory efforts. Upon accomplishment of the complete set of pre-defined development milestones, NuVasive will be obligated to purchase the remaining equity of Progentix for $45 million, and, upon the achievement of additional milestones and NuVasive's sales success, pay a maximum earn-out of $25 million. In addition, NuVasive obtained exclusive worldwide distribution rights as well as an exclusive option to purchase all of Progentix under certain circumstances.

Joost de Bruijn, PhD, chief executive officer of Progentix Orthobiology said: "We are extremely pleased to be working with NuVasive, a company that has built an impressive track record of growth in the spine market by consistently and successfully leveraging innovation. NuVasive's investment allows Progentix to continue developing its unique family of bone graft materials and allows the near term commercialization of these products."

The Progentix product portfolio currently consists of a novel family of calcium phosphate synthetic bone substitutes. The Progentix granules have demonstrated osteoinductive-like properties in preclinical models and require FDA clearance via a 510(k) pathway. A putty formulation of the product is currently under development. Progentix is a spin-out from Twente University, the Netherlands, and has close ties to Queen Mary University in London, UK, where Mr. de Bruijn is a Professor of Biomaterials and focuses on the research of Progentix' unique suite of biomaterials. Progentix, founded in 2007, obtained a series A financing from BioGeneration Ventures in early 2008, allowing the accelerated development of its groundbreaking technology.

About Progentix Orthobiology

Progentix Orthobiology B.V. was established in 2007 and develops CuriOs (TM), a unique suite of osteoinductive-like material products for clinical application in bone regenerative surgery. CuriOs is based on surface structured ceramic biomaterial scaffolds that, in preclinical testing, have shown the ability to attract stem cells after implantation.

W: http://www.progentix.com


'/>"/>
SOURCE Progentix Orthobiology
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Progentix Orthobiology B.V. Closes Series A Financing Round
2. Nuvasive Reports Third Quarter 2008 Financial Results
3. NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
4. NuVasive Completes Acquisition of Osteocel Biologics Business
5. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
6. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
9. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
10. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
11. NuVasive to Host Investor Reception on September 11, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
Breaking Biology News(10 mins):